(1S,4R)-4-[3-(cis-2,6-Dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-ylamine → 1-{(1S,4R)-4-[3-((2S,6R)-2,6-Dimethyl-piperidin-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-3-[1'-(2-hydroxy-ethyl)-3-ethyl-1'H-[1,4']bipyrazolyl-5-yl]-urea
Reaction equation
C[C@H]1CCC[C@@H](C)N1C1N2C=C(O[C@H]3C4C(=CC=CC=4)[C@@H](N)CC3)C=CC2=NN=1.[CH3:30][C@H:31]1[CH2:36][CH2:35][CH2:34][C@@H:33]([CH3:37])[N:32]1[C:38]1[N:42]2[CH:43]=[C:44]([O:47][C@H:48]3[C:57]4[C:52](=[CH:53][CH:54]=[CH:55][CH:56]=4)[C@@H:51]([NH:58][C:59](=[O:81])[NH:60][C:61]4[N:65]([C:66]5[CH:67]=[N:68][N:69]([CH2:71][CH2:72][O:73]S(C)(=O)=O)[CH:70]=5)[N:64]=[C:63]([CH:78](C)[CH3:79])[CH:62]=4)[CH2:50][CH2:49]3)[CH:45]=[CH:46][C:41]2=[N:40][N:39]=1>>[CH3:37][C@H:33]1[CH2:34][CH2:35][CH2:36][C@@H:31]([CH3:30])[N:32]1[C:38]1[N:42]2[CH:43]=[C:44]([O:47][C@H:48]3[C:57]4[C:52](=[CH:53][CH:54]=[CH:55][CH:56]=4)[C@@H:51]([NH:58][C:59]([NH:60][C:61]4[N:65]([C:66]5[CH:67]=[N:68][N:69]([CH2:71][CH2:72][OH:73])[CH:70]=5)[N:64]=[C:63]([CH2:78][CH3:79])[CH:62]=4)=[O:81])[CH2:50][CH2:49]3)[CH:45]=[CH:46][C:41]2=[N:40][N:39]=1Participants
3
Reactant 2
Product 1
Procedure
The title compound was prepared starting from Intermediate 3 (900 mg, 2.27 mmol), and Intermediate Cb (889 mg, 2.27 mmol) by using an analogous procedure to that described for Intermediate A step d. LCMS (Method 3): Rt 3.30 min, m/z=639 [MH+].
Sources & evidence
- ORD record
- ord-0c04ad777d0d4590a64724a1c561eebc
- Source dataset
- uspto-grants-2016_06
- Patent number
- US09359354B2
Reaction notes
Loading…